Neuca

Neuca EBITDA per Share

The EBITDA per Share of Neuca (NEU.WA) as of Oct 22, 2026 is 49.75 PLN. In the previous year, EBITDA per Share was 60.66 PLN — a change of -17.98% (lower).

EBITDA per Share

49.75PLN

YoY

-17.98%

Last updated:

EBITDA per Share of Neuca is 2025 49.75 PLN. EBITDA per Share of Neuca was 2024 60.66 PLN. It decreases by -17.98% lower compared to the previous year.

The Neuca EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
28.40 PLN
Jan 1, 2019
37.15 PLN
Jan 1, 2020
48.70 PLN
Jan 1, 2021
43.50 PLN
Jan 1, 2022
53.88 PLN
Jan 1, 2023
58.53 PLN
Jan 1, 2024
60.66 PLN
Jan 1, 2025
49.75 PLN
The Neuca EBITDA per Share history
YEAREBITDA per ShareYoY
49.75PLN-17.98%
60.66PLN+3.64%
58.53PLN+8.64%
53.88PLN+23.86%
43.50PLN-10.69%
48.70PLN+31.11%
37.15PLN+30.81%
28.40PLN+8.84%
26.09PLN-17.35%
31.57PLN+17.22%
26.93PLN+58.23%
17.02PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

EBITDA per Share of Neuca is 49.75 PLN in 2025.

EBITDA per Share of Neuca changed from 60.66 PLN to 49.75 PLN, representing a -17.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Neuca since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neuca

All Key Metrics — Neuca